Inclusion Criteria:  Age ≥18 years and ≤65 years. Histologically-confirmed cervical cancer, anal cancer, head and neck cancers with confirmed HPV16 infection and HLA-A*02:01 allele Failure on or intolerance to systemic therapy for unresectable advanced cancer. ECOG performance status of 0-1. Estimated life expectancy ≥ 3 months. Patients must have at least one measurable lesion defined by RECIST 1.1. Female patients of childbearing age must undergo a serum pregnancy test within 7 days prior to study treatment and the results must be negative, and are willing to use a very effective and reliable method of contraception from screening through 6 months after the last dose of study treatment. The patient must be willing to sign the informed consent form and have a good anticipation of compliance with study procedure.  Exclusion Criteria：  The proportion of T cell immune-related gene deletion mutations>5%. Patient received any genetically modified T cell therapy. Patient who is being treated with T cell immunosuppressive agent （such as cyclophosphamide, FK506,tripterygium glycosides） or T cell immunoagonist. Patients received chemotherapy, targeted therapy, immunotherapy, or other investigational agents within 2 weeks and received radiotherapy within 4 weeks before apheresis.  Patients with any organ dysfuntion as defined below:  leukocytes<3.0 x 109/L absolute neutrophil count >1.5 x 109/L hemoglobin<90g/L platelets <100 x 1010/L lymphocytes<0.8 x 109/L percentage of lymphocytes<15% creatinine>1.5×ULN or creatinine clearance <50mL/min total bilirubin>3×ULN; ALT/AST>3×ULN (patients with liver metastasis,>5×ULN) INR>1.5×ULN; APTT>1.5×ULN SpO2≤90% Patients with serious medical conditions, disorders, and / or comorbidities, including, but are not limited to: severe heart disease, cerebrovascular disease, epileptic seizures, uncontrolled diabetes (CTCAE 5.0: FBG ≥ 2 grade), active infection, active digestive tract Ulcer, gastrointestinal bleeding, intestinal obstruction, pulmonary fibrosis, renal failure, respiratory failure. Patient with a severe cardiovascular disease with 6 months before screening, including, but are not limited to, myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Heart failure NYHA grade Ⅲ or Ⅳ. Left Ventricular Ejection Fractions (LVEF) <50%. Patient with a known active brain metastases. Patient with a known myelodysplastic syndrome (MDS) or lymphoma. Patient with a known active autoimmune disease, including , but are not limited to, acquired or congenital immunodeficiency disease, allogeneic organ transplantation, autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease. Patient with a known active Hepatitis B or Hepatitis C. Patient with a history of Human Immunodeficiency Virus (HIV) . Patient with a history of syphilis. Pregnant or lactating women. Patient with a known active mental and neurological diseases. The principal investigator judged that it is not suitable to participate in this clinical study.